Novo Nordisk (NVO-4.34% ) teased some new details about a potential Ozempic successor during a call with investors Tuesday .
The Danish pharma giant fielded several questions from interested analysts about its next-gen GLP-1 medication CagriSema, regarding its efficacy, safety, and supply chain.
Novo Nordisk is known for its blockbuster GLP-1 drugs Wegovy and Ozempic . These drugs mimic a hormone that regulates appetite and blood sugar and have become highly sought after as treatments for obesity and Type 2 diabetes. Demand for these medications has turned Novo Nordisk and its rival Eli Lilly (LLY-3.74% ), the maker of competing medications Zepbound and Mounjaro, into the largest pharma companies in the world .
Novo Nordisk is currently developing an even more potent obesity and diabetes treatment. CagriSema combines semaglutide, the active ingredient in Ozempic and Wegovy, with an amylin and calcitonin receptor agonist. Amylin helps regulate blood sugar levels, similar to GLP-1, while calcitonin controls calcium levels in the blood.
A previous early-stage clinical trial of CagriSema found it helped patients lose on average 15.6% of their weight over 32 weeks . For comparison, the highest dose of Wegovy led to an average of 15% weight loss after 68 weeks in clinical trials.